Journal
JOURNAL OF SURGICAL ONCOLOGY
Volume 116, Issue 1, Pages 63-74Publisher
WILEY
DOI: 10.1002/jso.24627
Keywords
adoptive cell therapy; CAR T cells; chimeric antigen receptor; checkpoint blockade; immunotherapy
Funding
- Memorial Sloan-Kettering Cancer Center [SU2C-AACR-DT1012]
- National Cancer Institute [P30-CA008748]
- Congressionally Directed Medical Research Programs [BC132124, LC110202, PR101053]
- CDMRP [PR101053, 547075, LC110202, 545913, BC132124, 672101] Funding Source: Federal RePORTER
Ask authors/readers for more resources
Chimeric antigen receptor (CAR) T-cell therapy utilizes genetic engineering to redirect a patient's own T cells to target cancer cells. The remarkable results in hematological malignancies prompted investigating this approach in solid tumors such as pancreatic cancer. The complex tumor microenvironment, stromal hindrance in limiting immune response, and expression of checkpoint blockade on T cells pose hurdles. Herein, we summarize the opportunities, challenges, and state of knowledge in targeting pancreatic cancer with CAR T-cell therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available